Cargando…
Improved glycaemic control and treatment satisfaction with a simple wearable 3‐day insulin delivery device among people with Type 2 diabetes
AIM: To evaluate the PAQ (®) (CeQur SA, Horw, Switzerland), a wearable 3‐day insulin delivery device that provides set basal rates and bolus insulin on demand, in people with Type 2 diabetes. METHOD: Adults with Type 2 diabetes with HbA(1c) concentrations ≥53 and ≤97 mmol/mol (7.0 and 11.0%) while t...
Autores principales: | Mader, J. K., Lilly, L. C., Aberer, F., Poettler, T., Johns, D., Trautmann, M., Warner, J. L., Pieber, T. R. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6175230/ https://www.ncbi.nlm.nih.gov/pubmed/29888811 http://dx.doi.org/10.1111/dme.13708 |
Ejemplares similares
-
Developing a Simple 3-Day Insulin Delivery Device to Meet the Needs of People With Type 2 Diabetes
por: Lilly, Leslie C., et al.
Publicado: (2018) -
GlucoTab‐guided insulin therapy using insulin glargine U300 enables glycaemic control with low risk of hypoglycaemia in hospitalized patients with type 2 diabetes
por: Aberer, Felix, et al.
Publicado: (2018) -
Day-and-night glycaemic control with closed-loop insulin delivery versus conventional insulin pump therapy in free-living adults with well controlled type 1 diabetes: an open-label, randomised, crossover study
por: Bally, Lia, et al.
Publicado: (2017) -
Faster insulin action is associated with improved glycaemic outcomes during closed‐loop insulin delivery and sensor‐augmented pump therapy in adults with type 1 diabetes
por: Ruan, Yue, et al.
Publicado: (2017) -
Day-to-day fasting glycaemic variability in DEVOTE: associations with severe hypoglycaemia and cardiovascular outcomes (DEVOTE 2)
por: Zinman, Bernard, et al.
Publicado: (2017)